Atorvastatin cost-effectiveness
Pro Research Analysisby 
Searched over 200M research papers for "atorvastatin cost-effectiveness"
Atorvastatin Cost-Effectiveness in Cardiovascular Disease Prevention
Cost-Effectiveness in Real-World and Clinical Settings
Multiple studies have shown that atorvastatin is a cost-effective option for preventing cardiovascular events. In a large German cohort of patients undergoing percutaneous coronary intervention (PCI), high-potency statins like atorvastatin provided a clinical benefit in reducing all-cause death, with an incremental cost-effectiveness ratio (ICER) of €6,311 per quality-adjusted life year (QALY) in the base case, and up to €12,216/QALY in scenario analyses, indicating favorable cost-effectiveness in real-world practice . Similarly, in Iran, atorvastatin was found to be highly cost-effective for cardiovascular disease prevention, with a cost of only $173 per additional QALY compared to no intervention .
Atorvastatin in Primary and Secondary Prevention
For primary prevention in patients with type 2 diabetes, atorvastatin demonstrated an ICER of £6,471 per QALY, well below the UK’s accepted threshold, confirming its cost-effectiveness in this population . In secondary prevention, high-dose atorvastatin was found to be cost-effective compared to generic simvastatin in Denmark, Norway, and Sweden, especially in high-risk patients, with the cost per QALY gained ranging from €35,210 to €62,639 depending on the country and patient risk profile .
Comparison with Other Statins
Several studies compared atorvastatin with simvastatin. Atorvastatin enabled more patients to reach LDL cholesterol targets, though at a slightly higher drug cost. The incremental cost per additional patient achieving target LDL-C was $1,088 annually in Canada, and the model was sensitive to drug cost and effectiveness assumptions . In Australia, atorvastatin achieved greater cholesterol reduction and a higher percentage of patients reaching target levels, with overall healthcare costs lower than for simvastatin, making it more cost-effective for achieving national health targets . Literature reviews and market analyses in Belgium also concluded that generic atorvastatin is more cost-effective than simvastatin, especially at higher doses, and is expected to dominate the statin market while generating substantial savings for healthcare payers Simoens2012Simoens2012.
Economic Impact of Generic Atorvastatin
The introduction of generic atorvastatin has significantly improved its cost-effectiveness. In Belgium, price reductions of 50–70% for generic atorvastatin are projected to save €108.6–€215.2 million annually, with atorvastatin becoming the dominant statin by market share Simoens2012Simoens2012. Economic models in managed-care settings also suggest that starting patients on branded atorvastatin and switching to generic versions is a cost-saving strategy compared to continued use of other generic statins .
Quality-Adjusted Life Years and Event Avoidance
Across studies, atorvastatin consistently showed favorable cost per QALY and per cardiovascular event avoided. For example, in the ASCOT-LLA trial, the incremental cost per event avoided was €11,693–€12,673, supporting the use of atorvastatin as a cost-effective strategy for patients with hypertension and no prior coronary heart disease .
Conclusion
Overall, evidence from diverse healthcare systems and patient populations shows that atorvastatin is a cost-effective intervention for both primary and secondary prevention of cardiovascular disease. Its cost-effectiveness is enhanced with the availability of generic formulations, and it often outperforms other statins like simvastatin in achieving cholesterol targets and reducing cardiovascular events, making it a valuable choice for healthcare payers and patients alike Nuehrenberg2020Raikou2007Lachaine2007+7 MORE.
Sources and full results
Most relevant research papers on this topic